The invention belongs to the area of medicine and can be used as a therapeutic substance and as an inhibitor of the growth of Helicobacter pylori during anti-helicobacter therapy. The invention targets the development of a new therapeutic substance that does not cause adverse reactions or side effects in the liver, blood and other organs and is capable of suppressing H. Pylori growth and the progression of infection. Chlorophyll-carotene paste (CGNC) is used as an active ingredient of the pharmaceutical composition for anti-helicobacter therapy, Bioeffective A. It is an inhibitor of H. pylori. CGNC can be included as a therapeutic substance in anti-helicobacter therapy. The pharmaceutical composition for anti-helicobacter therapy contains a therapeutically effective amount of chlorophyll-carotene paste and pharmaceutically acceptable carriers and/or solvents. The pharmaceutical mixture is in the form of solution, suspension, capsule, or tablets. The method of conducting anti-helicobacter therapy includes administration of an effective amount of CGNC paste to patients in drug form or as part of a pharmaceutical mixture.
